Q BIOMED INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0002 USD | +100.00% |
|
0.00% | -50.00% |
| 2023 | Q BioMed Inc. Reports Earnings Results for the First Quarter Ended February 28, 2023 | CI |
| 2023 | Q BioMed Inc. Reports Earnings Results for the Full Year Ended November 30, 2022 | CI |
Valuation
| Fiscal Period: November | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 52.51 | 27.77 | 26.75 | 25.75 | 12.93 | 1.349 |
| Enterprise Value (EV) 1 | 51.69 | 27.96 | 30.27 | 25.67 | 15.64 | 5.409 |
| P/E ratio | -3.23 x | -2.89 x | -2.34 x | -1.7 x | -1.39 x | -0.2 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | 858,387,667 x | 66,116,970 x | 4,744,992 x |
| EV / Revenue | - | - | - | 855,555,667 x | 79,967,019 x | 19,023,098 x |
| EV / EBITDA | - | - | -3,798,186 x | -1,959,974 x | -2,131,385 x | -1,593,012 x |
| EV / FCF | -34.5 x | -7.97 x | -37 x | -12.5 x | -11.4 x | 10.2 x |
| FCF Yield | -2.9% | -12.5% | -2.7% | -8.01% | -8.77% | 9.83% |
| Price to Book | 154 x | -264 x | -6.25 x | -3.19 x | -1.2 x | -0.14 x |
| Nbr of stocks (in thousands) | 11,695 | 14,240 | 16,721 | 23,411 | 28,599 | 84,328 |
| Reference price 2 | 4.490 | 1.950 | 1.600 | 1.100 | 0.4522 | 0.0160 |
| Announcement Date | 2/28/18 | 3/7/19 | 2/28/20 | 3/1/21 | 2/28/22 | 5/26/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: November | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | 0.03 | 0.1956 | 0.2844 |
| EBITDA | - | - | -7.97 | -13.1 | -7.339 | -3.396 |
| EBIT 1 | -12.37 | -9.02 | -8.02 | -13.15 | -7.389 | -3.446 |
| Operating Margin | - | - | - | -43,818.05% | -3,777.44% | -1,211.74% |
| Earnings before Tax (EBT) 1 | -14.54 | -9.271 | -10.28 | -13.49 | -8.241 | -2.052 |
| Net income 1 | -14.54 | -9.271 | -10.28 | -13.49 | -8.241 | -2.052 |
| Net margin | - | - | - | -44,973.97% | -4,213.02% | -721.67% |
| EPS 2 | -1.389 | -0.6750 | -0.6835 | -0.6476 | -0.3264 | -0.0800 |
| Free Cash Flow 1 | -1.497 | -3.507 | -0.8173 | -2.055 | -1.372 | 0.5319 |
| FCF margin | - | - | - | -6,849.95% | -701.54% | 187.06% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 2/28/18 | 3/7/19 | 2/28/20 | 3/1/21 | 2/28/22 | 5/26/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: November | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 0.19 | 3.52 | - | 2.71 | 4.06 |
| Net Cash position 1 | 0.82 | - | - | 0.08 | - | - |
| Leverage (Debt/EBITDA) | - | - | -0.4414 x | - | -0.3691 x | -1.196 x |
| Free Cash Flow 1 | -1.5 | -3.51 | -0.82 | -2.05 | -1.37 | 0.53 |
| ROE (net income / shareholders' equity) | 1,724% | -7,401% | 399% | 441% | 286% | 44.1% |
| ROA (Net income/ Total Assets) | -674% | -280% | -261% | -1,300% | -645% | -99.6% |
| Assets 1 | 2.159 | 3.309 | 3.935 | 1.038 | 1.279 | 2.061 |
| Book Value Per Share 2 | 0.0300 | -0.0100 | -0.2600 | -0.3400 | -0.3800 | -0.1200 |
| Cash Flow per Share 2 | 0.0700 | 0.1900 | 0.0100 | 0.0100 | 0.0100 | 0 |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 2/28/18 | 3/7/19 | 2/28/20 | 3/1/21 | 2/28/22 | 5/26/23 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -50.00% | 29.02K | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- QBIO Stock
- Financials Q BioMed Inc.
